Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy | Valuation: AUD7.70This is a key result in line with our research thesis.Trofinetide (formerly NNZ-2566) is Neuren’s primary asset and has been exclusively licensed to Acadia Pharmaceuticals (NASDAQ:ACAD) for North America. Today Acadia announced a robustly positive Phase 3 clinical trial outcome.This result derisks NEU and adds ~40% to our valuation at initiation.
Development Neuren Pharmaceuticals (NEU-ASX) | Speculative Buy |...
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.21 |
Change
-0.270(1.74%) |
Mkt cap ! $1.940B | |||
| Open | High | Low | Value | Volume |
| $15.20 | $15.33 | $15.02 | $2.486M | 163.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 254 | $15.21 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.22 | 819 | 18 |
View Market Depth
| Last trade - 11.31am 22/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |